Navigation Links
Heparin Use Prior to Endoscopic Vein Harvest Improves Graft Patency in Off-Pump Coronary Artery Bypass Patients
Date:6/8/2009

Pre-heparinization Limits Clot Retention and Decreases Residual Clot Volume

SAN FRANCISCO, June 8 /PRNewswire/ -- MAQUET Cardiovascular LLC announced today that data presented at the annual meeting of the International Society for Minimally Invasive Cardiothoracic Surgery show that administration of a heparin bolus with doses as low as 2500U prior to endoscopic vein harvest (EVH) was associated with improved acute saphenous vein (SV) graft patency in patients undergoing off-pump coronary artery bypass (OPCAB). Pre-heparinization was also linked to a significant reduction in the incidence and volume of residual clot strands within the vein.

In EVH, a small incision is made in the leg, through which an endoscope is passed and the vein harvested for coronary artery bypass graft (CABG) procedures. This method reduces patient discomfort and scarring.

EVH also significantly reduces wound complications and hastens recovery time compared to traditional techniques that involve a long incision to expose the entire length of the vein.

"In our experience, the impact of pre-heparinization on surgical bleeding is minimal, making it a promising strategy that may improve patient outcomes with minimally invasive vein harvesting," said lead investigator Robert Poston, M.D., Chief, Division of Cardiac Surgery, Boston University.

The prospective study examined acute patency rates in 460 patients that underwent OPCAB using veins acquired through EVH, comparing patients receiving no heparin prior to harvest (n=306) to those who received one of three doses of heparin prior to the procedure (n=181). A subset of the most recent 110 patients underwent catheter-based infrared imaging (OCT) of the full tract of harvested SV in order to measure residual clot within the vein. Overall, vein graft patency was 98.9 percent in patients treated with heparin compared to 95.2 percent in the controls (p<0.05). In the subset of the most recent patients, 42 percent of patients receiving pre-heparinization showed residual clot in the harvested vein compared with 85 percent of patients that didn't receive heparin (p<0.05). Clot volume and the percentage of the vein containing clot were also significantly reduced with the use of heparin prior to EVH.

"These data are evidence that with pre-heparinization, EVH can be performed with excellent patency results in patients who require coronary artery bypass grafting, reinforcing the efficacy of this procedure," said Dr. Poston.

"We are encouraged by the results of this study and see it as a true advance in patient care," said Pat Walsh, Chief Operating Officer of the Cardiac Surgery division of MAQUET. "As a leader in EVH, MAQUET is committed to helping physicians continue to optimize EVH conduit quality and patient outcomes."

About MAQUET Cardiovascular

MAQUET Cardiovascular LLC is a division of MAQUET Medical Systems, part of the publicly listed Swedish group of companies GETINGE AB. MAQUET Cardiovascular was recently formed by combining MAQUET Cardiopulmonary with Boston Scientific's Vascular Surgery and Cardiac Surgery divisions, which includes the products and services of Guidant Cardiac Surgery and the VASOVIEW endoscopic vessel harvesting system. The creation of this new organization enables MAQUET to offer a comprehensive array of patient care solutions for less-invasive endoscopic vessel harvesting, off- and on-pump coronary artery bypass surgery and vascular grafts.

MAQUET has 170 years of healthcare experience, and is committed to becoming "The Gold Standard" for therapeutic medical equipment across the globe. As a market leader, MAQUET offers innovative medical solutions from three divisions: Surgical Workplaces, Critical Care and Cardiovascular.

http://www.maquet.com


'/>"/>
SOURCE MAQUET Cardiovascular LLC
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Interface Biologics Anti-Thrombic Additives Show Equivalent Efficacy to Commercial Heparinized Coatings
2. ISAR-REACT 3 Pits Bivalirudin vs. Unfractionated Heparin in PCI
3. Study Shows That Low-Molecular Weight Heparin (LMWH) was Associated with Reduced Hospital Costs of Venous Thromboembolism (VTE) Treatment Compared with Unfractionated Heparin (UFH)
4. Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment
5. Alimera Sciences Iluvien(TM) Phase 3 Studies for DME Pass Final DSMB Review Prior to October Readout
6. Blood Testing Identifies Abnormal Cells Up to Six Years Prior to Leukemia Diagnosis
7. FDA Grants Priority Review of a Supplemental Biologics License Application for Cinryze(TM) C1 Inhibitor (Human) as Treatment for Acute Attacks of Hereditary Angioedema (HAE)
8. RAD001 Phase II Trial Results Positive in Patients with Advanced Gastric Cancer After Failure of One or More Prior Treatments
9. ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments
10. RAD001 Granted Priority Review in the US Based on Potential to Fill Unmet Medical Need in Patients With Advanced Kidney Cancer
11. REMOXY(R) NDA Filing Accepted by FDA and Priority Review Granted
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... F ast access to ... at the point of need   ... and services, has launched a ClinicalKey mobile app that enables ... Elsevier designed the mobile app to allow users to select access to ... Android and iOS formats for mobile phone and tablet. ...
(Date:2/11/2016)... , Feb. 11, 2016 Scientists ... cell-isolation method that opens the door to genetic ... now have been impossible to isolate with 100 ... isolate specific tumor types in various stages of ... variants of these cells that are clinically relevant, ...
(Date:2/11/2016)... , Feb. 11, 2016  NanoViricides, Inc. ... it has entered into an agreement with the ... nanoviricides® drug candidates in standard animal models of ... , Research Director. Dr. Romanowski has extensive experience ... --> Eric Romanowski , Research ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... February 11, 2016 , ... From March ... Academy of Dermatology Annual Meeting at the Walter E. Washington Convention Center in ... for both the condition of hyperhidrosis (excessive sweating) and its treatment options. Specifically, ...
(Date:2/11/2016)... ... February 11, 2016 , ... Husted Kicking has completed its Third ... February 6th & 7th, 2016 according to kicking coach Michael Husted. , “This event ... the NFL’s combine in Indianapolis,” says Husted. “The NFL uses a third party organization ...
(Date:2/11/2016)... ... February 11, 2016 , ... The book, “Computers Should ... services, what questions to ask your IT consultant before signing a contract and how ... computer network. , “With companies relying heavily on e-mail and technology, it’s more important ...
(Date:2/11/2016)... ... February 11, 2016 , ... As part of their 2015 end of ... Round Table Foundation (MDRTF), has gifted $10,000 to University of Chicago to support ovarian ... Billy Cundiff. , “We are honored to support a promising young investigator from Dr. ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... as the World Molecular Imaging Congress (WMIC), will be held in New York ... meeting is “Imaging Biology…Improving Therapy.” The congress will highlight and emphasize how imaging ...
Breaking Medicine News(10 mins):